Joanne L. Blum
About
Joanne L. Blum is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Joanne L. Blum has authored 93 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 35 papers in Cancer Research. Recurrent topics in Joanne L. Blum's work include Cancer Treatment and Pharmacology (46 papers), Advanced Breast Cancer Therapies (40 papers) and Breast Cancer Treatment Studies (28 papers). Joanne L. Blum is often cited by papers focused on Cancer Treatment and Pharmacology (46 papers), Advanced Breast Cancer Therapies (40 papers) and Breast Cancer Treatment Studies (28 papers). Joanne L. Blum collaborates with scholars based in United States, France and Spain. Joanne L. Blum's co-authors include Joyce O’Shaughnessy, Anthony Gonçalvès, Henri Roché, Jennifer K. Litton, Hope S. Rugo, Lida A. Mina, Sara A. Hurvitz, Johannes Ettl, Ruben G.W. Quek and W. Eiermann and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
In The Last Decade
Joanne L. Blum
92 papers receiving 5.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Joanne L. Blum United States | 28 | 4.7k | 1.9k | 1.5k | 1.3k | 831 | 93 | 5.6k | ||
| Grazia Arpino Italy | 37 | 4.2k 0.9× | 2.8k 1.5× | 1.6k 1.1× | 1.7k 1.4× | 1.6k 1.9× | 157 | 6.7k | ||
| Tiffany A. Traina United States | 30 | 2.4k 0.5× | 1.6k 0.8× | 1.4k 0.9× | 1.1k 0.9× | 698 0.8× | 146 | 4.0k | ||
| Rinat Yerushalmi Israel | 27 | 4.4k 0.9× | 2.3k 1.2× | 1.8k 1.2× | 2.2k 1.8× | 1.2k 1.4× | 119 | 6.7k | ||
| Yun Gong United States | 35 | 1.9k 0.4× | 1.1k 0.6× | 1.0k 0.7× | 1.1k 0.9× | 364 0.4× | 118 | 3.6k | ||
| Hervé Bonnefoi France | 31 | 2.8k 0.6× | 2.5k 1.3× | 994 0.7× | 1.6k 1.3× | 588 0.7× | 135 | 5.0k | ||
| Gaia Schiavon United Kingdom | 28 | 2.5k 0.5× | 1.9k 1.0× | 1.7k 1.1× | 1.5k 1.2× | 339 0.4× | 105 | 4.6k | ||
| Shaheenah Dawood United Arab Emirates | 32 | 3.4k 0.7× | 2.3k 1.2× | 1.4k 1.0× | 989 0.8× | 383 0.5× | 109 | 5.1k | ||
| Stacy L. Moulder United States | 32 | 2.5k 0.5× | 1.3k 0.7× | 922 0.6× | 1.4k 1.1× | 313 0.4× | 141 | 3.9k | ||
| Rita Nanda United States | 34 | 4.3k 0.9× | 2.5k 1.3× | 1.4k 1.0× | 1.5k 1.2× | 765 0.9× | 205 | 6.3k | ||
| Dhananjay Chitale United States | 32 | 2.3k 0.5× | 2.0k 1.0× | 2.9k 2.0× | 2.1k 1.6× | 342 0.4× | 106 | 5.4k |
Countries citing papers authored by Joanne L. Blum
Since
Specialization
Citations
This map shows the geographic impact of Joanne L. Blum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joanne L. Blum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joanne L. Blum more than expected).
Fields of papers citing papers by Joanne L. Blum
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Joanne L. Blum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joanne L. Blum. The network helps show where Joanne L. Blum may publish in the future.
Co-authorship network of co-authors of Joanne L. Blum
This figure shows the co-authorship network connecting the top 25 collaborators of Joanne L. Blum. A scholar is included among the top collaborators of Joanne L. Blum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joanne L. Blum. Joanne L. Blum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rocque, Gabrielle B., Joanne L. Blum, Yan Ji, et al.. (2024). Abstract PO3-05-11: Enhancing the interpretation of real-world quality of life (QoL) in patients (pts) with hormone receptor positive human epidermal growth factor 2 negative (HR+/HER2−) advanced breast cancer (ABC) enrolled in the POLARIS trial. Cancer Research. 84(9_Supplement). PO3–5.
2.
Rocque, Gabrielle B., Joanne L. Blum, Yan Ji, et al.. (2024). Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Breast Cancer Research and Treatment. 209(3). 613–627.
3.
Tripathy, Debu, Joanne L. Blum, Meghan Karuturi, et al.. (2023). 373P Impact of comorbidities on real-world (rw) clinical outcomes of patients (pts) with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) treated with palbociclib and enrolled in POLARIS. Annals of Oncology. 34. S332–S332.
4.
Blum, Joanne L., David J. Gordon, Meghan Karuturi, et al.. (2023). Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study. Breast Cancer Research and Treatment. 203(3). 463–475.
5.
Rocque, Gabrielle B., Joanne L. Blum, Yan Ji, et al.. (2022). 266P Real-world quality of life (QoL) in patients with HR+/HER2-advanced breast cancer (ABC) treated with palbociclib: Final clinical outcome assessment (COA) analysis from POLARIS. Annals of Oncology. 33. S659–S659.
6.
Litton, Jennifer K., Sara A. Hurvitz, Lida A. Mina, et al.. (2020). Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Annals of Oncology. 31(11). 1526–1535.
7.
Rocque, Gabrielle B., Joanne L. Blum, Aldemar Montero, et al.. (2019). Understanding palbociclib practice patterns in a real-world setting.. Journal of Clinical Oncology. 37(27_suppl). 200–200.
8.
Litton, Jennifer K., Hope S. Rugo, Johannes Ettl, et al.. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine. 379(8). 753–763.
9.
Blum, Joanne L., Anthony Gonçalvès, Noa Efrat, et al.. (2016). A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment. 155(2). 295–302.
10.
O’Shaughnessy, Joyce, Hartmut Koeppen, Yuanyuan Xiao, et al.. (2015). Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clinical Cancer Research. 21(19). 4305–4311.
11.
Holmes, Frankie A., Virginia Espina, Lance A. Liotta, et al.. (2013). Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. BMC Research Notes. 6(1). 507–507.
12.
Leonard, Robert, Bryan T. Hennessy, Joanne L. Blum, & Joyce O’Shaughnessy. (2011). Dose-Adjusting Capecitabine Minimizes Adverse Effects While Maintaining Efficacy: A Retrospective Review of Capecitabine for Metastatic Breast Cancer. Clinical Breast Cancer. 11(6). 349–356.
13.
Twelves, Chris, Danuta Z. Loesch, Joanne L. Blum, et al.. (2010). A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane.. Journal of Clinical Oncology. 28(18_suppl). CRA1004–CRA1004.
14.
Cortés, Javier, Linda T. Vahdat, Joanne L. Blum, et al.. (2010). Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology. 28(25). 3922–3928.
15.
Jones, Stephen E., Frankie A. Holmes, Joyce O’Shaughnessy, et al.. (2009). Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. Journal of Clinical Oncology. 27(8). 1177–1183.
16.
Jones, Stephen E., Christopher Stokoe, Mark D. Sborov, et al.. (2008). The Effect of Tamoxifen or Exemestane on Bone Mineral Density During the First 2 Years of Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer. Clinical Breast Cancer. 8(6). 527–532.
17.
Blum, Joanne L., Michael A. Savin, Gerald M. Edelman, et al.. (2007). Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes. Clinical Breast Cancer. 7(11). 850–856.
18.
O’Shaughnessy, Joyce & Joanne L. Blum. (2006). Capecitabine/Taxane Combination Therapy: Evolving Clinical Utility in Breast Cancer. Clinical Breast Cancer. 7(1). 42–50.
19.
Blum, Joanne L., Elizabeth Claire Dees, Judith O. Hopkins, et al.. (2006). Phase II Trial of Capecitabine and Weekly Paclitaxel As First-Line Therapy for Metastatic Breast Cancer. Journal of Clinical Oncology. 24(27). 4384–4390.
20.
O’Shaughnessy, Joyce, Joanne L. Blum, Vladimir Moiseyenko, et al.. (2001). Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Annals of Oncology. 12(9). 1247–1254.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Grazia Arpino Breakdown of academic impact, for papers by Tiffany A. Traina Breakdown of academic impact, for papers by Rinat Yerushalmi Breakdown of academic impact, for papers by Yun Gong Breakdown of academic impact, for papers by Hervé Bonnefoi Breakdown of academic impact, for papers by Gaia Schiavon Breakdown of academic impact, for papers by Shaheenah Dawood Breakdown of academic impact, for papers by Stacy L. Moulder Breakdown of academic impact, for papers by Rita Nanda Breakdown of academic impact, for papers by Dhananjay Chitale